Core Viewpoint - The announcement details significant changes in the board of directors at Sanofi Pharmaceuticals-B (02257), including resignations and new appointments, effective from various dates in 2025 [1]. Group 1: Board Resignation - Ms. Huang Mengying has resigned from multiple positions including independent non-executive director and chairman of the board, effective December 1, 2025, to focus on decentralized life sciences and expand her law firm in China [1]. - After her resignation, Ms. Huang will remain as a company advisor [1]. Group 2: New Appointments - Dr. Yin Huijun has been appointed as a non-executive director, effective September 1, 2025 [1]. - Ms. Lu Yixing, OBE, has been appointed as an independent non-executive director, effective September 1, 2025 [1]. - Dr. Pan Honghui, the current executive director and CEO, will become the chairman of the board, effective December 1, 2025 [1]. Group 3: Committee Changes - Dr. Pan has also been appointed as the authorized representative, effective December 1, 2025 [1]. - Mr. Ouyang Yunlong has been appointed as a member of the audit and remuneration committees, effective September 1, 2025 [1]. - Mr. Wang Yushan has been appointed as a member of the remuneration and investigation committees, effective September 1, 2025 [1]. - Dr. Zhang Peng has been appointed as the chairman of the remuneration committee, effective December 1, 2025, and as a member of the nomination and investigation committees, effective September 1, 2025 [1]. - Ms. Lu has been appointed as the chairman of the nomination committee, effective October 18, 2025, the chairman of the investigation committee, effective December 1, 2025, and as a member of the audit committee, effective September 1, 2025 [1].
圣诺医药-B(02257)：殷惠军获委任为非执行董事